CD8A and neoplasm: Consistent with this result, intra-tumor injection of STING agonist could not only induce strong CD8+ T cells responses but also induce Th1 differentiation or reduce the suppressive Foxp3+ Treg populations to a large extent to exert anti-tumor effects (41, 54, 55).